ICU Medical CFO Sells 6,381 Shares for $1.1 Million

Brian Michael Bonnell, Chief Financial Officer of ICU Medical(NASDAQ:ICUI), sold 6,381 shares of common stock on Sept. 1, 2026, according to a recent SEC Form 4 filing.

Transaction summary

Metric	Value
Transaction value	$1.1 million
Shares sold	6,381
Post-transaction shares (directly held)	56,062
Post-transaction value	$9.5 million

Transaction value based on SEC Form 4 weighted average sale price ($175); post-transaction value based on Sept. 1, 2026, market close ($170.81).

Key questions

• Under what conditions was this equity sale executed?
  The transaction was carried out pursuant to a Rule 10b5-1 trading plan that Bonnell adopted on June 1, 2026. These plans allow corporate insiders to schedule share sales at a predetermined time to mitigate concerns regarding the use of material non-public information.
• What is the CFO's remaining direct equity exposure in the company?
  Following the completion of this transaction, the CFO maintains direct ownership of 56,062 shares. At the Sept. 1, 2026, market close of $170.81, this remaining direct position is valued at approximately $9.5 million.
• How has the stock performed leading up to this disposal?
  The $175-per-share sale occurred against a backdrop of positive equity performance, with ICU Medical delivering a 34% one-year total return as of the Sept. 1, 2026, transaction date.
• What is the broader context of insider ownership at the firm?
  While this transaction reduced the CFO's individual direct holding, total insider ownership at the medical technology firm stands at 0.2% of shares outstanding. The company continues to operate with a market capitalization of $4.3 billion as of the Aug. 31, 2026, market close.

Company Overview

Metric	Value
Share Price (as of market close 2026-08-31)	$172.95
Market Capitalization	$4.3 billion
Revenue (TTM)	$2.2 billion
Net Income (TTM)	$30.1 million

Company Snapshot

• ICU Medical develops, manufactures, and sells specialized medical devices for infusion therapy and critical care applications, including needle-free connectors, catheter maintenance solutions, and hemodialysis equipment that generate the majority of the company's revenue.
• The company operates a global manufacturing and distribution model, leveraging proprietary technology platforms to deliver integrated solutions across hospital systems, dialysis centers, and healthcare providers worldwide.
• ICU Medical primarily serves acute care hospitals, dialysis facilities, and healthcare systems that require advanced infusion and critical care solutions to improve patient safety and clinical outcomes.

ICU Medical is a global medical technology leader with approximately 13,000 employees and a market capitalization of $4.3 billion, generating $2.2 billion in TTM revenue. The company maintains a competitive position through its portfolio of proprietary needle-free and disinfection technologies that address critical safety and infection control challenges in clinical settings. ICU Medical demonstrates robust market demand for its specialized infusion therapy and critical care solutions.

What this transaction means for investors

On Sept. 1, Bonnell sold 6,381 shares in a transaction valued at $1.1 million. Initially, that sounds like a large number of shares and a large dollar amount that were sold. However, looking at the transaction, this is largely routine and nothing for shareholders to be alarmed over. The sale was part of a trading plan established in June, so it wasn't a knee-jerk reaction, a spur-of-the-moment decision, or anything that would signal there was anything amiss with ICU Medical. Also, Bonnell still holds more than 56,000 shares, indicating continued alignment with ICU Medical's success.

The company recently showed strength in its 2026 second-quarter earnings report, with generally accepted account principles (GAAP) gross profit increasing from $208.1 million to $235.1 million. In the report, the company also raised its GAAP net income forecast from $26 million to $44 million to $73 million to $83 million. Overall, the company's shares are up 18.4% over the last 12 months, while the S&P 500 is up 15.7%. That should give investors greater confidence in the company's state, as Bonnell's sale shouldn't raise any alarms.

Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.